Gilead Sciences (NASDAQ:GILD) had its price target decreased by Leerink Swann from $86.00 to $83.00 in a research note issued to investors on Wednesday. Leerink Swann currently has a market perform rating on the biopharmaceutical company’s stock.
Several other research firms have also recently issued reports on GILD. Vetr cut Gilead Sciences from a buy rating to a hold rating and set a $91.25 target price for the company. in a research note on Monday, January 29th. Citigroup raised Gilead Sciences from a neutral rating to a buy rating and dropped their price objective for the company from $88.80 to $76.00 in a research note on Tuesday, January 30th. Bank of America lifted their price objective on Gilead Sciences from $82.00 to $87.00 and gave the company a neutral rating in a research note on Wednesday. Morgan Stanley dropped their price objective on Gilead Sciences from $87.00 to $84.00 and set an equal weight rating for the company in a research note on Wednesday. Finally, Barclays reaffirmed an overweight rating and issued a $90.00 price objective on shares of Gilead Sciences in a research note on Wednesday, October 11th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $86.56.
Shares of Gilead Sciences (NASDAQ GILD) opened at $79.32 on Wednesday. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.55. The stock has a market capitalization of $103,613.26, a price-to-earnings ratio of 22.79, a price-to-earnings-growth ratio of -1.75 and a beta of 1.22. Gilead Sciences has a one year low of $63.76 and a one year high of $89.54.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.11. The company had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm’s quarterly revenue was down 18.7% compared to the same quarter last year. During the same quarter last year, the firm earned $2.70 earnings per share. equities analysts expect that Gilead Sciences will post 6.41 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be issued a $0.57 dividend. The ex-dividend date of this dividend is Thursday, March 15th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a yield of 2.87%. Gilead Sciences’s dividend payout ratio (DPR) is 59.77%.
In related news, EVP Gregg H. Alton sold 25,000 shares of Gilead Sciences stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $83.51, for a total value of $2,087,750.00. Following the completion of the transaction, the executive vice president now directly owns 62,738 shares in the company, valued at $5,239,250.38. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Chairman John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $83.56, for a total value of $4,178,000.00. Following the completion of the transaction, the chairman now owns 3,046,766 shares of the company’s stock, valued at $254,587,766.96. The disclosure for this sale can be found here. Over the last quarter, insiders sold 578,333 shares of company stock valued at $44,100,508. 1.30% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in the stock. Welch Investments LLC purchased a new stake in Gilead Sciences during the 3rd quarter worth about $108,000. Wealthcare Advisory Partners LLC purchased a new stake in Gilead Sciences during the 3rd quarter worth about $133,000. Horan Capital Advisors LLC. purchased a new stake in Gilead Sciences during the 3rd quarter worth about $144,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Gilead Sciences during the 2nd quarter worth about $147,000. Finally, Hanson & Doremus Investment Management lifted its holdings in Gilead Sciences by 806.5% during the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 1,613 shares during the last quarter. Hedge funds and other institutional investors own 75.84% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://ledgergazette.com/2018/02/11/leerink-swann-trims-gilead-sciences-gild-target-price-to-83-00.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.